TERTIARY STRUCTURE DATA |
Homo sapiens
|
theoretical model |
0.00 Å |
1BXF |
1BXF |
1BXF |
1BXF |
1BXF |
1BXF |
|
Cys25Ser mutant |
2.20 Å |
1GLO |
1GLO |
1GLO |
1GLO |
1GLO |
1GLO |
Turkenburg et al., 2002 |
complex with dipeptide nitrile inhibitor BLN |
1.90 Å |
1MS6 |
1MS6 |
1MS6 |
1MS6 |
1MS6 |
1MS6 |
Ward et al., 2002 |
complex with inhibitor C1P |
2.00 Å |
1NPZ |
1NPZ |
1NPZ |
1NPZ |
1NPZ |
1NPZ |
Pauly et al., 2003 |
complex with inhibitor C4P |
1.80 Å |
1NQC |
1NQC |
1NQC |
1NQC |
1NQC |
1NQC |
Pauly et al., 2003 |
precursor Cys25Ala mutant |
2.10 Å |
2C0Y |
2C0Y |
2C0Y |
2C0Y |
2C0Y |
2C0Y |
Kaulmann et al., 2006 |
complex with non-covalent 2-(benzoxazol-2- ylamino)-acetamide |
1.90 Å |
2F1G |
2F1G |
2F1G |
2F1G |
2F1G |
2F1G |
Tully et al., 2006 |
complex with CRA-27934, a nitrile inhibitor |
1.90 Å |
2FRA |
2FRA |
2FRA |
2FRA |
2FRA |
2FRA |
|
complex with inhibitor CRA-26871 |
1.60 Å |
2FRQ |
2FRQ |
2FRQ |
2FRQ |
2FRQ |
2FRQ |
|
complex with inhibitor CRA-29728 |
1.70 Å |
2FT2 |
2FT2 |
2FT2 |
2FT2 |
2FT2 |
2FT2 |
|
complex with inhibitor CRA-27566 |
1.95 Å |
2FUD |
2FUD |
2FUD |
2FUD |
2FUD |
2FUD |
|
complex with irreversible inhibitor CRA-14013 |
2.20 Å |
2FYE |
2FYE |
2FYE |
2FYE |
2FYE |
2FYE |
|
complex with vinyl sulfone inhibitor CRA-14009 |
2.50 Å |
2G6D |
2G6D |
2G6D |
2G6D |
2G6D |
2G6D |
|
complex with inhibitor CRA-16981 |
2.00 Å |
2G7Y |
2G7Y |
2G7Y |
2G7Y |
2G7Y |
2G7Y |
|
complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide |
1.50 Å |
2H7J |
2H7J |
2H7J |
2H7J |
2H7J |
2H7J |
Patterson et al., 2006 |
complex with N-[(1R)-1-[(benzylsulfonyl)methyl]-2-[(1S)-1-methyl-2-[4-(trifluoromethoxy)phenyl]aminoethyl]amino-2-oxoethyl]morpholine-4-carboxamide |
1.80 Å |
2HH5 |
2HH5 |
2HH5 |
2HH5 |
2HH5 |
2HH5 |
Tully et al., 2006 |
complex with non covalent arylaminoethyl amide. |
1.55 Å |
2HHN |
2HHN |
2HHN |
2HHN |
2HHN |
2HHN |
Tully et al., 2006 |
complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide |
1.90 Å |
2HXZ |
2HXZ |
2HXZ |
2HXZ |
2HXZ |
2HXZ |
Patterson et al., 2006 |
complex with a novel 2- arylphenoxyacetaldehyde inhibitor derived by the substrate activity screening (sas) method |
1.60 Å |
2OP3 |
2OP3 |
2OP3 |
2OP3 |
2OP3 |
2OP3 |
Inagaki et al., 2007 |
complex with compound 15 |
1.97 Å |
2R9M |
2R9M |
2R9M |
2R9M |
2R9M |
2R9M |
|
complex with compound 26 |
2.00 Å |
2R9N |
2R9N |
2R9N |
2R9N |
2R9N |
2R9N |
|
complex with compound 8 |
2.00 Å |
2R9O |
2R9O |
2R9O |
2R9O |
2R9O |
2R9O |
|
complex with a pyrazole-based inhibitor with an arylalkynes as P1 binding element |
2.18 Å |
3IEJ |
3IEJ |
3IEJ |
3IEJ |
3IEJ |
3IEJ |
|
complex with 4-(3-trifluoromethylphenyl)-pyrimidine-2-carbonitrile |
1.60 Å |
3N3G |
3N3G |
3N3G |
3N3G |
3N3G |
3N3G |
|
complex with 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile |
1.90 Å |
3N4C |
3N4C |
3N4C |
3N4C |
3N4C |
3N4C |
|
complex with a covalent inhibitor with an aldehyde warhead |
1.49 Å |
3OVX |
3OVX |
3OVX |
3OVX |
3OVX |
3OVX |
|
complex with a non-covalent inhibitor |
1.80 Å |
4P6E |
4P6E |
4P6E |
4P6E |
4P6E |
4P6E |
|
complex with a non-covalent inhibitor. |
1.58 Å |
4P6G |
4P6G |
4P6G |
4P6G |
4P6G |
4P6G |
|
complex with bound ligand |
2.78 Å |
5QBU |
5QBU |
5QBU |
5QBU |
5QBU |
5QBU |
|
complex with bound ligand |
1.80 Å |
5QBV |
5QBV |
5QBV |
5QBV |
5QBV |
5QBV |
|
complex with bound ligand |
3.01 Å |
5QBW |
5QBW |
5QBW |
5QBW |
5QBW |
5QBW |
|
complex with bound ligand |
2.10 Å |
5QBX |
5QBX |
5QBX |
5QBX |
5QBX |
5QBX |
|
complex with bound ligand |
2.25 Å |
5QBY |
5QBY |
5QBY |
5QBY |
5QBY |
5QBY |
|
complex with bound ligand |
2.80 Å |
5QBZ |
5QBZ |
5QBZ |
5QBZ |
5QBZ |
5QBZ |
|
complex with bound ligand |
1.90 Å |
5QC0 |
5QC0 |
5QC0 |
5QC0 |
5QC0 |
5QC0 |
|
complex with bound ligand |
2.08 Å |
5QC1 |
5QC1 |
5QC1 |
5QC1 |
5QC1 |
5QC1 |
|
complex with bound ligand |
2.26 Å |
5QC2 |
5QC2 |
5QC2 |
5QC2 |
5QC2 |
5QC2 |
|
complex with bound ligand |
2.00 Å |
5QC3 |
5QC3 |
5QC3 |
5QC3 |
5QC3 |
5QC3 |
|
complex with bound ligand |
2.00 Å |
5QC4 |
5QC4 |
5QC4 |
5QC4 |
5QC4 |
5QC4 |
|
complex with bound ligand |
2.40 Å |
5QC5 |
5QC5 |
5QC5 |
5QC5 |
5QC5 |
5QC5 |
|
complex with bound ligand |
2.10 Å |
5QC6 |
5QC6 |
5QC6 |
5QC6 |
5QC6 |
5QC6 |
|
complex with bound ligand |
1.90 Å |
5QC7 |
5QC7 |
5QC7 |
5QC7 |
5QC7 |
5QC7 |
|
complex with bound ligand |
1.74 Å |
5QC8 |
5QC8 |
5QC8 |
5QC8 |
5QC8 |
5QC8 |
|
complex with bound ligand |
2.00 Å |
5QC9 |
5QC9 |
5QC9 |
5QC9 |
5QC9 |
5QC9 |
|
complex with bound ligand |
2.29 Å |
5QCA |
5QCA |
5QCA |
5QCA |
5QCA |
5QCA |
|
complex with bound ligand |
2.20 Å |
5QCB |
5QCB |
5QCB |
5QCB |
5QCB |
5QCB |
|
complex with bound ligand |
1.80 Å |
5QCC |
5QCC |
5QCC |
5QCC |
5QCC |
5QCC |
|
complex with bound ligand |
2.78 Å |
5QCE |
5QCE |
5QCE |
5QCE |
5QCE |
5QCE |
|
complex with bound ligand |
2.10 Å |
5QCF |
5QCF |
5QCF |
5QCF |
5QCF |
5QCF |
|
complex with bound ligand |
2.70 Å |
5QCG |
5QCG |
5QCG |
5QCG |
5QCG |
5QCG |
|
complex with bound ligand |
2.20 Å |
5QCH |
5QCH |
5QCH |
5QCH |
5QCH |
5QCH |
|
complex with bound ligand |
2.18 Å |
5QCI |
5QCI |
5QCI |
5QCI |
5QCI |
5QCI |
|
complex with bound ligand |
2.00 Å |
5QCJ |
5QCJ |
5QCJ |
5QCJ |
5QCJ |
5QCJ |
|
Mus musculus
|
theoretical model; precursor |
0.00 Å |
1M0H |
1M0H |
1M0H |
1M0H |
1M0H |
1M0H |
|
mature peptidase |
2.00 Å |
4BPV |
4BPV |
4BPV |
4BPV |
4BPV |
4BPV |
|
mature peptidase |
1.70 Å |
4BQV |
4BQV |
4BQV |
4BQV |
4BQV |
4BQV |
|
mature peptidase |
1.25 Å |
4BS5 |
4BS5 |
4BS5 |
4BS5 |
4BS5 |
4BS5 |
Hilpert et al., 2013 |
mature peptidase |
1.20 Å |
4BS6 |
4BS6 |
4BS6 |
4BS6 |
4BS6 |
4BS6 |
|
mature peptidase |
1.96 Å |
4BSQ |
4BSQ |
4BSQ |
4BSQ |
4BSQ |
4BSQ |
Hilpert et al., 2013 |
mature peptidase |
1.47 Å |
4MZO |
4MZO |
4MZO |
4MZO |
4MZO |
4MZO |
Hilpert et al., 2013 |
mature peptidase |
1.85 Å |
4MZS |
4MZS |
4MZS |
4MZS |
4MZS |
4MZS |
Hilpert et al., 2013 |